INTU vs LLY: Which Is the Better Buy?
Side-by-side comparison of Intuit Inc. and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-17.
Intuit Inc. · Technology
$279.70
+45.0% upside to fair value
Grade A
High Quality
VS
Eli Lilly and Company · Healthcare
$1,179.09
+31.7% upside to fair value
High Conviction
Grade A
High Quality
QuantHub Verdict
INTU has more upside to fair value
(+45.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
INTU |
LLY |
| Current Price |
$279.70 |
$1,179.09 |
| Fair Value Estimate |
$405.56 |
$1,552.32 |
| Upside to Fair Value |
+45.0%
|
+31.7%
|
| Market Cap |
$76.5B |
$1,110.4B |
| Forward P/E |
16.9x
|
—
|
| EV / EBITDA |
11.2x
|
34.3x
|
| Price / Sales |
3.7x
|
14.6x
|
| Price / FCF |
9.9x
|
77.7x
|
| Revenue Growth YoY |
+10.4%
|
+55.5%
|
| Gross Margin |
81.0%
|
83.5%
|
| Operating Margin |
27.5%
|
45.9%
|
| Return on Equity |
23.3%
|
101.3%
|
| Dividend Yield |
0% |
0.55% |
| FCF Yield |
10.08%
|
1.29%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
Intuit Inc. is a leading technology company specializing in software applications for financial management, including popular products like TurboTax and QuickBooks. The company demonstrates high business quality with a durable competitive moat supported by strong brand recognition, high gross margins of 81%, and a robust return on equity of 23.3%. Despite a moderate revenue growth of 10.4% and ea…
Eli Lilly is a global biopharma company whose exceptionally profitable cardiometabolic franchises, led by Mounjaro and Zepbound, are driving a high-quality growth phase: revenue rose 55.5% year over year and earnings rose 168.0% year over year in the most recent quarter, while gross, operating, and net margins were 83.5%, 45.9%, and 35.0%, respectively. Business quality is high because tirzepatid…
Accumulation Zones
| Metric |
INTU |
LLY |
| Zone Low |
$304.17 |
$1,164.24 |
| Zone High |
$344.73 |
$1,319.47 |
| In Buy Zone? |
Yes
|
Yes
|